ERBB2 and breast carcinoma: Other than HER2 amplification, HER2 gene mutations are also found in about 4% of multiple breast cancer types,9, 10, 11 exerting an oncogenic effect and indicating an additional patient group that may potentially be targeted with HER2‐directed therapies.12